(1) The Prescription Drug Affordability Board established in ORS 646A.693 shall develop a plan for establishing upper payment limits on drugs sold in this state that are subject to affordability reviews under ORS 646A.694. The plan shall include:\n(a) A methodology for establishing upper payment limits;\n(b) An analysis of the resources needed by the board to implement the plan;\n(c) An analysis of how upper payment limits would be enforced; and\n(d) An analysis of how upper payment limits could be implemented with respect to:\n(A) Plans administered by the Public Employees’ Benefit Board;\n(B) Plans administered by the Oregon Educators Benefit Board;\n(C) Other state-administered health benefits;\n(D) Health benefit plans, as defined in ORS 743B.005; and\n(E) Other forms of insurance that provide pharmaceutical benefits, to the extent permitted by federal law.\n(2) No later than September 15, 2024, the Prescription Drug Affordability Board shall report to the interim committees of the Legislative Assembly related to health, in the manner provided in ORS 192.245, the following information:\n(a) A detailed explanation of the plan developed under subsection (1) of this section.\n(b) Legislative Assembly related to health, in the manner provided in ORS 192.245, the following information:\n(a) A detailed explanation of the plan developed under subsection (1) of this section.\n(b) An analysis of potential savings from or costs of implementing the plan with respect to:\n(A) The state;\n(B) Insurers;\n(C) Hospitals;\n(D) Pharmacies; and\n(E) Consumers. [2023 c.466 §3]\nNote:\n646A.685 was enacted into law by the Legislative Assembly but was not added to or made a part of ORS chapter 646A or any series therein by legislative action. See Preface to Oregon Revised Statutes for further explanation.
Oregon Legal Code